camonsertib + olaparib

Camonsertib + olaparib is a combination therapy of camonsertib, an oral, potent, and selective inhibitor of Ataxia-Telangiectasia and Rad3-related protein kinase (ATR), and olaparib, a small molecule inhibitor of poly (ADP-ribose) polymerase (PARP). The combination is being evaluated in patients with advanced solid tumors, especially those harboring alterations in DNA damage response (DDR) genes such as BRCA1, BRCA2, and ATM. This approach aims to exploit synthetic lethality by simultaneously targeting ATR-mediated DNA damage sensing/repair and PARP-driven single-strand break repair, potentially overcoming resistance to PARPi monotherapy. Early-phase clinical trials (TRESR, ATTACC; NCT04497116, NCT04972110) have shown promising safety and efficacy signals across multiple tumor types, with the greatest benefit observed in late-line ovarian cancer. The regimen uses intermittent, low-dose scheduling to mitigate overlapping hematological toxicities while maintaining anti-tumor activity[1][2][5][6].

Other names

camonsertib + olaparibRP-3500 + olaparib